ライフサイエンスコーパス: bleed

1 he 414 operated thyroid lobes, 2.4% (n = 10) bled.

2 tervention) and nonmajor clinically relevant bleeding.

3 in-hospital mortality and in-hospital major bleeding.

4 of TF (TFshort) in a woman with unexplained bleeding.

5 rillation, including those with high risk of bleeding.

6 aution is needed in patients at high risk of bleeding.

7 d sides, 4.7% (n = 6) suffered postoperative bleeding.

8 Three patients (23.1%) had significant bleeding.

9 nd polyps or cancer as possible causes of GI bleeding.

10 utaneous coronary intervention (PCI)-related bleeding.

11 may aid in assessing the individual risk of bleeding.

12 sms that are associated with heavy menstrual bleeding.

13 truction, severe symptoms, and a low risk of bleeding.

14 ignificantly higher risk of gastrointestinal bleeding.

15 of AC with mortality, intubation, and major bleeding.

16 The principal safety outcome was major bleeding.

17 s associated with an increased rate of major bleeding.

18 sex hormones, may reduce fibroid-associated bleeding.

19 level category and 90-day symptomatic VTE & bleeding.

20 ations or if medical treatment fails to stop bleeding.

21 was associated with a reduced risk of major bleeding.

22 al bleeding and minimize the risk of delayed bleeding.

23 oke and the primary safety outcome was major bleeding.

24 termediate, and 2447 (48.8%) as low risk for bleeding.

25 III) and most often presents with unexpected bleeding.

26 antithrombin itself may increase the risk of bleeding.

27 h direct oral anticoagulant-associated major bleeding.

28 f endoscopy for acute upper gastrointestinal bleeding.

29 coronary syndrome but with increased risk of bleeding.

30 g these patients against the excess risk for bleeding.

31 g FVIII activity >=50% abolished the risk of bleeding.

32 I, and stroke without increasing the risk of bleeding.

33 these women are still at risk of postpartum bleeding.

34 on and with an acceptable associated risk of bleeding.

35 hort course (<=30 days) associated with less bleeding.

36 sm (1.58, 1.14-2.19, p=0.01), but less major bleeding (0.60, 0.47-0.75, p<0.0001) than those in treat

37 c stroke, 0.92 (95% CI, 0.75-1.12) for major bleeding, 0.54 (95% CI, 0.39-0.76) for cardiovascular de

38 (159 of 334 patients, 48%), gastrointestinal bleeding (127 of 334 patients, 38%), or a combination of

39 bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18).

40 een high aFXa and 90-day clinically relevant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.

41 ut of 657 lesions (2.7%) resulted in delayed bleeding: 7 (1.1%) in hemoclip group and 11 (1.7%) in no

42 Society on Thrombosis and Haemostasis major bleeding a secondary safety outcome.

43 Bleeding was defined as Bleeding Academic Research Consortium (BARC) 2, 3, or 5,

44 In the elderly or low-weight group, Bleeding Academic Research Consortium type 3 to 5 bleedi

45 Procedure-related bleeding was defined as Bleeding Academic Research Consortium type 4 severe blee

46 s the incidence of bleeding defined as BARC (Bleeding Academic Research Consortium) type 3 to 5 bleed

47 on baseline levels of pocket depth, gingival bleeding, ACH, and smoking status.

48 Post-discharge bleeding after ACS is associated with a similar increase

49 by P2Y12 inhibitor monotherapy reduces major bleeding after percutaneous coronary intervention with d

50 There was no recurrence of bleeding after reintervention.

51 Thus, the risk of new bleeds after a first diagnosis of AHA remains high until

52 grade 2 = development of varices; grade 3 = bleeding alone; grade 4 = nonbleeding single decompensat

53 Bleeding and altered iron distribution occur in multiple

54 ll as significantly reduced gastrointestinal bleeding and anemia in inducible ALK1-deficient adult mi

55 7 of 334 patients, 38%), or a combination of bleeding and ascites (38 of 334 patients, 11%).

56 ompromising hemostasis, thus causing serious bleeding and increased morbidity and mortality.

57 KA to DOAC is an intermittent risk factor of bleeding and ischemic stroke in patients with AF.

58 ools and techniques to treat intraprocedural bleeding and minimize the risk of delayed bleeding.

59 ssess the association between post-discharge bleeding and subsequent mortality after ACS according to

60 compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter a

61 blishment of a therapeutic range to minimize bleeding and thrombosis is important for personalized tr

62 at can potentially increase the risk of both bleeding and thrombosis.

63 tality, irrespective of periprocedural major bleeding and vascular complications.

64 analysis is to assess the tradeoff of risk (bleeding) and benefit (ischemic events) over time with a

65 s of malignancy (eg, dysphagia, weight loss, bleeding) and those with other main risk factors for eso

66 her risk for stroke/systemic embolism, major bleeding, and all-cause death than the standard-dose pop

67 nt rates per 100 patients for MI, CVD, major bleeding, and all-cause hospitalization were similar for

68 , acute cerebrovascular disease (CVD), major bleeding, and all-cause hospitalization.

69 cations including pancreatitis, cholangitis, bleeding, and perforation between the two groups (P > 0.

70 g depth, clinical attachment level, gingival bleeding, and radiographic alveolar crestal height (ACH)

71 g Academic Research Consortium type 4 severe bleeding, and therefore most bleeding at the puncture si

72 d enough additive activity to allow complete bleeding arrest.

73 use did not modify the likelihood of delayed bleeding as related to the following variables: use of a

74 mbolism, fatal pulmonary embolism, and major bleeding as secondary endpoints.

75 does not seem to correlate with the risk of bleeding as suggested from previous studies.

76 rgeting of modifiable risk factors for major bleeding, as well as the application of decision rules t

77 icoagulant effects ex vivo and in vivo (tail-bleeding assay and FeCl(3)-induced thrombosis).

78 n vivo by reducing blood loss in a mice tail bleeding assay.

79 come, major or clinically relevant non-major bleeding (assessed in participants who received >=1 dose

80 ng Academic Research Consortium) type 3 to 5 bleeding at 1 year after randomization.

81 outcomes including death, stroke, and major bleeding at 30 days and 1 year were compared by OAC type

82 m type 4 severe bleeding, and therefore most bleeding at the puncture site was counted as non-procedu

83 l, critical, or clinically overt bleeding or bleeding at the surgical site leading to intervention) a

84 Most bleeding at the TAVI puncture site was counted as non-pr

85 Use of bleeding avoidance strategies and bridging therapy were

86 Bleeding avoidance strategies such as radial artery acce

87 l relationship between aspirin use and major bleeding based on aspirin use in the 7 days prior to ant

88 in the incidence of delayed PPB and days to bleeding between two groups (0.8% vs 1.3%, p = 0.4; 3.4

89 Thrombocytopenia and bleeding (both grade 3/4 but fully reversible) occurred

90 icacy and are associated with lower rates of bleeding, but costs limit use for some patients.

91 PCI significantly reduced the risk of major bleeding by 40% compared with dual antiplatelet therapy

92 ation of aspirin after 1 to 3 months reduced bleeding by 50% (1.78% versus 3.58%; HR, 0.50 [95% CI, 0

93 GI bleeding can also occur in patients affected by acquired

94 ata than nonprocedural outcomes (eg, stroke, bleeding, cardiogenic shock).

95 Warfarin was associated with more bleeding compared to no AC.

96 DOACs had a lower incidence of bleeding compared to warfarin in exploratory analyses.

97 transfemoral PCI, VCD+BIV had lower odds of bleeding compared with no BAS across all risk strata.

98 y was associated with reduced risk for major bleeding compared with triple therapy (risk difference [

99 between the PT and ST groups with regard to bleeding complications (3.5% vs 10.3%, p=0.099), tracheo

100 A lack of consensus on the management of bleeding complications in patients with NS indicates an

101 Severe bleeding complications may be lower with rivaroxaban tha

102 Vascular and bleeding complications were commonly reported in transca

103 on rules to identify patients at low risk of bleeding complications, in whom long-term anticoagulant

104 The 30-day clinical events (vascular and bleeding complications, stroke, acute kidney injury, and

105 iated with an increased risk of grade 3 to 4 bleeding complications.

106 The PRECISE-DAPT, PARIS, and DAPT (bleeding component) risk scores were applied in the TRIL

107 Gpr56 (-/-) mice have prolonged bleeding, defective platelet plug formation, and delayed

108 The secondary end point was the incidence of bleeding defined as BARC (Bleeding Academic Research Con

109 asurements included the presence of gingival bleeding, dental fracture, dental fluorosis, and dental

110 ps appears feasible with acceptable rates of bleeding despite early experience.

111 owever, the 10-year risk of gastrointestinal bleeding did not differ significantly between users and

112 Immune thrombocytopenia (ITP) is an acquired bleeding disorder characterized by antibody-mediated pla

113 Bleeding disorders have recently been described in patie

114 Women with inherited bleeding disorders, including carriers of hemophilia A a

115 If bleeding does occur, standard guidelines for the managem

116 ectively analyzed patients with intracranial bleeding due to an AVM who were included in a prospectiv

117 illebrand disease, have an increased risk of bleeding during pregnancy and delivery.

118 ytic situations can lead to life-threatening bleeding, especially during cardiac surgery.

119 n humanized mice, but neither causes serious bleeding, establishing a causal link between partial ago

120 Patients with a bleeding event had a 10.8% mortality (hazard ratio [HR],

121 unique patients (19.7%) experienced a major bleeding event.

122 ation while 7.6% (n=2651) had an in-hospital bleeding event.

123 including a higher proportion of in-hospital bleeding events (3.8% vs. 0.8%; p = 0.011), 2-year all-c

124 dpoints included safety (determined by major bleeding events [time-to-event analysis on the treated s

125 l approaches in assessing total ischemic and bleeding events after percutaneous coronary intervention

126 Procedural complications included 10 bleeding events and 1 stroke.

127 substantial reduction in annualized rates of bleeding events and complete cessation of prophylactic f

128 onotherapy consistently reduced ischemic and bleeding events by 5% to 8%, compared with conventional

129 Rates of both vascular complications and bleeding events decreased over time (P value for trend t

130 ow-molecular-weight heparin group, and minor bleeding events in 478 (12.1%) of 3945 patients with ava

131 Major bleeding events occurred in 71 (1.7%) of 4139 patients i

132 There were 19 bleeding events recorded among 16 individuals.

133 ter; the median number of annualized treated bleeding events was 0, and the median use of exogenous f

134 s, and a 42% relative risk increase in major bleeding events was used for the 5-year number needed to

135 Bleeding events were also associated with 30-day death (

136 Bleeding events were assessed by treating physicians.

137 Re-bleeding events were increased after challenge, but bloo

138 1.0%) reporting clinically relevant nonmajor bleeding events, and 37 (18.2%) minor bleeding events.

139 Primary end points included VTE recurrence, bleeding events, and mortality at 6 and 12 months.

140 rence, and 3 of 203 (1.5%) experienced major bleeding events, with 2 (1.0%) reporting clinically rele

141 nmajor bleeding events, and 37 (18.2%) minor bleeding events.

142 were in-hospital vascular complications and bleeding events.

143 myocardial infarction at the expense of more bleeding events.

144 Prespecified safety outcomes included major bleeding (fatal, critical, or clinically overt bleeding

145 ion of BIV to TRI did not change the odds of bleeding for any risk strata.

146 zation, for salvage therapy, and for diffuse bleeding from malignancy.

147 : Endoscopists should understand the risk of bleeding from therapeutic endoscopic interventions (eg,

148 d clinically significant early postoperative bleeding (>10 mL/kg per 4 hours).

149 a, there was a wide variation in outcomes of bleeding (>2.5-fold variation), and death, acute kidney

150 th; loose, crooked, or stained teeth; and/or bleeding gums), and lack of social participation.

151 Patients with warfarin-associated major bleeding had longer median length of stay (11 vs 6 d; p

152 Patients with intestinal bleeding had the fastest eculizumab clearance, required

153 cephalopathy [HE]) who were within 7 days of bleeding had their HVPG measured before and at 1-3 month

154 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34 [95% CI, 0.14-0.80]) and ma

155 ]) and major or clinically relevant nonmajor bleeding (hazard ratio, 0.35 [95% CI, 0.17-0.72]) compar

156 sion, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international

157 ke, ischemic stroke, hemorrhagic stroke, and bleeding hospitalizations in ESRD patients treated with

158 ith an increased risk of hospitalization for bleeding (HR: 1.26; 95% CI: 1.09 to 1.46; p = 0.0017) an

159 ale) score was 4.6 +/- 1.5, and the mean HAS-BLED (hypertension, abnormal renal/liver function, strok

160 h poor platelet recovery were more likely to bleed if given a prophylactic platelet transfusion (odds

161 This circumvents chances of re-bleed if standard bronchial artery embolisation is done

162 ular events, splanchnic vein thrombosis, and bleeding in a cohort with cirrhosis and atrial fibrillat

163 thout persistent mild bleeding or any severe bleeding in a post hoc analysis.

164 define future strategies for prophylaxis of bleeding in AHA.

165 tibody, as a non-FVIII alternative to reduce bleeding in hemophilia A, the question of how much clott

166 rin on survival, venous thromboembolism, and bleeding in patients with cancer in general and by type.

167 I) is the main predictor of postparacentesis bleeding in patients with cirrhosis.

168 iver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatiti

169 Bleeding in target joints resolved in five of six partic

170 the following question: "Did you notice any bleeding in your gums?" Demographic, socioeconomic, and

171 Neither bleeding incidence nor hemodynamic response is significa

172 corded: visible plaque index (VPI), gingival bleeding index (GBI), probing depth (PD), clinical attac

173 meters (plaque index, gingival index, sulcus bleeding index, probing depth, and clinical attachment l

174 Nonetheless, gastric variceal bleeding is more severe and associated with worse outcom

175 Although arterial bleeding is the main cause of postoperative hemorrhage,

176 of hospitalized medical patients for VTE and bleeding; it also informs guidelines for VTE prevention

177 s of vascular complications like significant bleeding, limb ischemia, and cannula site bleeding were

178 reast lump, post-menopausal bleeding, rectal bleeding, lower urinary tract symptoms, haematuria, chan

179 is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have no

180 cipants <70 years of age not at high risk of bleeding (n=3540).

181 esults suggest that the presence of gingival bleeding negatively impacts the social life of adolescen

182 osil(R) alone was used 211 (51.0%) times and bleeding occurred in 1.4% (n = 3).

183 ISTH major bleeding occurred in 140 patients in the rivaroxaban gro

184 Non-procedure-related bleeding occurred in 50 patients (15.1%) and 83 patients

185 Major bleeding occurred in 54 (10.7%) and 56 (11.0%) in the n-

186 ing Academic Research Consortium type 3 to 5 bleeding occurred in 8.1% of patients assigned to receiv

187 n occurred in one (1%) patient and grade 3-4 bleeding occurred in three (3%) patients.

188 Bleeding occurred on >=1 day in 19% of patients on 8% of

189 Major bleeding occurs in 1.1% of patients treated with direct

190 ociated with an increased short-term risk of bleeding (odds ratio = 1.42; 95% confidence intervals: 1

191 ociated to worsened SRP outcomes in terms of bleeding on probing (BOP) (OR = 1.02, P <0.05) and mean

192 Probing depth (PD), attachment level, bleeding on probing (BOP), and interproximal plaque inde

193 Bleeding on probing (BOP), plaque index, and probing dep

194 h (PD), clinical attachment level (CAL), and bleeding on probing (BOP).

195 uction in the percentage of sites exhibiting bleeding on probing (primary outcome) and lower levels o

196 inal bone loss [MBL], plaque index [PI], and bleeding on probing [BOP] in shamma users and non-users

197 Gingival status (bleeding on probing) and oral hygiene effectiveness (den

198 parameters, including pocket probing depth, bleeding on probing, and clinical attachment level were

199 significant correlations with plaque scores, bleeding on probing, and RF-IgA.

200 iodontal assessment was performed, including bleeding on probing, probing depth, and clinical attachm

201 graphic parameters, including probing depth, bleeding on probing, visual inspection, and radiographic

202 00 platelets/muL and without persistent mild bleeding or any severe bleeding in a post hoc analysis.

203 eeding (fatal, critical, or clinically overt bleeding or bleeding at the surgical site leading to int

204 l bleeding who were at high risk for further bleeding or death, endoscopy performed within 6 hours af

205 th endoscopic treatment of sites with active bleeding or high-risk stigmata for rebleeding.

206 an also had a lower rate of gastrointestinal bleeding or intracranial hemorrhage (12.9 per 1000 perso

207 with increased risks of hospitalization for bleeding or intracranial hemorrhage.

208 Additional bleeding or MIs resulted in a poorer prognosis.

209 re home, patients with previous intracranial bleeding or recent acute bleeding (such as gastrointesti

210 Ulcers with active bleeding or visible vessels were found on initial endosc

211 ferences in the risk of acute MI, CVD, major bleeding, or all-cause hospitalization after treatment i

212 re identified for the risk of MI, CVD, major bleeding, or all-cause hospitalization when comparing th

213 outcome of death, disabling stroke, serious bleeding, or cardiac arrest.

214 In total, 820 patients experienced a primary bleeding outcome and 937 experienced MACE.

215 nalysis, we compared the risk of 3 composite bleeding outcomes and 3 composite ischemic outcomes from

216 the SG and three from the nSG had immediate bleeding (P >0.05), while delayed bleeding was observed

217 ger age (p = 0.009), but not with chest tube bleeding (p = 0.18), other bleeding requiring RBC transf

218 temic embolism (p interaction = 0.26), major bleeding (p interaction = 0.25), and death (p interactio

219 8) and major or clinically relevant nonmajor bleeding (P interaction=0.05).

220 ajor vascular complications (P=0.044), major bleeding (P=0.041), and RBC transfusion (P=0.048) were i

221 ent acute bleeding (such as gastrointestinal bleeding), patients with acute ischaemic stroke and pati

222 ged >80 years with multiple risk factors for bleeding), patients with dementia or those living in a l

223 0], P-interaction=0.59), but increased major bleeding (PCI: 3.3% versus 2.0%; HR, 1.72 [95% CI, 1.34-

224 with an aged platelet population displayed a bleeding phenotype.

225 on platelet count are confounded by variable bleeding phenotypes, there is a need to identify new obj

226 Delayed post-polypectomy bleeding (PPB) is a major complication of polypectomy.

227 e; I: drug, infection, surgery, and variceal bleeding; R: systemic inflammatory response syndrome (SI

228 The crude bleeding rate was 4.4% overall.

229 tivity was significantly associated with the bleeding rate, but only achieving FVIII activity >=50% a

230 ore 0 vs higher) was associated with a lower bleeding rate.

231 The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95%

232 ll, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95

233 (abnormal mole, breast lump, post-menopausal bleeding, rectal bleeding, lower urinary tract symptoms,

234 lity, venous thromboembolism occurrence, and bleeding related outcomes through multivariable hierarch

235 For nonstroke bleeding-related hospitalizations, greater reductions wi

236 t with chest tube bleeding (p = 0.18), other bleeding requiring RBC transfusion (p = 0.75), fibrinoge

237 ema on chest x-ray, acute renal dysfunction, bleeding requiring transfusion or intervention, hypotens

238 safety outcomes were recurrent VTE and major bleeding, respectively.

239 High bleeding risk (HBR) patients undergoing percutaneous cor

240 clinical criteria to define patients at high bleeding risk (HBR).

241 to LMWH, DOACs showed no difference in major bleeding risk (RR 1.31; 95% CI 0.78-2.18; p = 0.31), tho

242 ent benefits for stroke prevention with less bleeding risk and less tedious monitoring requirements c

243 modes of DAPT cessation and outcomes across bleeding risk groups.

244 Stroke and bleeding risk models have been created and validated.

245 ng to their risk of bleeding using the PARIS bleeding risk score.

246 In patients with increased bleeding risk, the biolimus A9-coated BioFreedom stent,

247 in cardiovascular disease, but it increases bleeding risk.

248 able link between antithrombotic therapy and bleeding risk.

249 tting in rabbits, all without increasing the bleeding risk.

250 evaluation of the individual thrombotic and bleeding risks related to both clinical and procedural f

251 R 1.60; 95% CI 1.13-2.26; p = 0.008) and all bleeding (RR 1.49; 95% CI 1.10-2.01; p = 0.010).

252 Conversely, the risks of major bleeding (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (RR, 1.

253 bstruction syndrome; serious infections; WHO Bleeding Scale; transfusion requirements; and reactions

254 Mucosal and skin bleeding scores, number of previous treatments, age, and

255 ard guidelines for the management of DIC and bleeding should be followed.

256 rom "old" ones such as suspected small bowel bleeding (still the main indication for SBCE) to newer o

257 evious intracranial bleeding or recent acute bleeding (such as gastrointestinal bleeding), patients w

258 elic variants in NBEAL2 and characterized by bleeding symptoms, the absence of platelet alpha-granule

259 To assess the factors responsible for bleeding tendency in AKI, we performed a prospective stu

260 ast, factor XIII was lower in AKI (increased bleeding tendency).

261 boembolic complications and a higher risk of bleeding than an antiplatelet-based strategy.

262 use death, myocardial reinfarction, or major bleeding), the individual components of the primary end

263 ient and are thought to have a lower risk of bleeding; they are less suitable if there is a higher ri

264 tion, fasciotomy, acute kidney injury, major bleeding, transfusion, vascular complications, length of

265 by providing optimal protection against all bleed types, with less frequent doses.

266 (2018) using criteria that also evaluated bleeding upon probing.

267 plify the risk stratification after variceal bleeding using clinical data and HVPG.

268 were categorized according to their risk of bleeding using the PARIS bleeding risk score.

269 HCR reduces bleeding, ventilator time, and length of stay compared w

270 operative hemorrhage, most often no actively bleeding vessel can be found during revision.

271 catheter-based procedure performed to treat bleeding vessels.

272 a-operative complications were found such as bleeding, vitreous tube placement, bent tubes, etc.

273 Gingival bleeding was assessed through adolescent self-perception

274 The risk of perforation and bleeding was comparable.

275 Procedure-related bleeding was defined as Bleeding Academic Research Conso

276 Bleeding was defined as Bleeding Academic Research Conso

277 was done, and details of cases in which the bleeding was from a non-bronchial source were archived a

278 From 30 days to 6 months, the risk of severe bleeding was higher with aspirin than placebo (absolute

279 Severe bleeding was more frequent with ticagrelor.

280 k of the composite of recurrent VTE or major bleeding was nonsignificantly lower with DOACs than with

281 strong association between aspirin and major bleeding was observed for recent initiators of aspirin (

282 immediate bleeding (P >0.05), while delayed bleeding was observed in two subjects from the SG and th

283 ived IV emicizumab 24 hours before tail-clip bleeding was performed.

284 The incidence of ISTH major bleeding was significantly higher with rivaroxaban and a

285 FXIII-B have reduced FXIII-A without severe bleeding, we hypothesized that a suitable small interfer

286 nt bleeding, limb ischemia, and cannula site bleeding were 15.4% (95% CI, 8.6-23.7%), 12.6% (95% CI,

287 Rates of delayed bleeding were compared between the hemoclip and no-hemoc

288 in the risks of ischemic end points or major bleeding were observed with midterm or short-term DAPT f

289 nstrated a trend toward lower rates of major bleeding when compared with those with CrCl >30 mL/min (

290 2Y(12) inhibitor monotherapy reduces risk of bleeding when stopped 1 to 3 months after PCI.

291 points were myocardial infarction and major bleeding, which constituted the net clinical benefit.

292 n patients with acute upper gastrointestinal bleeding who were at high risk for further bleeding or d

293 percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) a

294 We evaluated the risk of major bleeding with concomitant therapy compared with anticoag

295 n that may be considered in cases of massive bleeding with poor visualization, for salvage therapy, a

296 olysis in Myocardial Infarction) major/minor bleeding with time-dependent c-indices.

297 Thrombolysis in Myocardial Infarction) major bleeding, with International Society on Thrombosis and H

298 Further bleeding within 30 days occurred in 28 patients (10.9%)

299 e related death or adverse events, and major bleeding within 72 hours after BEC directed therapy.

300 use death, myocardial reinfarction, or major bleeding, within 180 days.